Valneva SE (VALN) Operating Expenses (2021 - 2026)
Valneva SE (VALN) posted quarterly Operating Expenses of -$21.8 million for Q1 2026, up 2.7% year-on-year from -$21.3 million in Q1 2025, and down 108.87% on a QoQ basis from $246.0 million in Q4 2025.
Valneva SE (VALN) Operating Expenses (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Operating Expenses for 6 consecutive years, with -$21.8 million the latest figure, recorded in Q1 2026.
- Quarterly Operating Expenses rose 2.7% year-over-year to -$21.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.4 million (up 5.17% YoY) and the FY2025 annual result came in at $158.8 million, up 6.03% from the prior year.
- Operating Expenses declined to -$21.8 million in Q1 2026 per VALN's latest filing, from $246.0 million in the prior quarter.
- Over the last five years, Operating Expenses for VALN reached as high as $12.0 billion in Q3 2022 and fell as low as -$11.8 billion in Q4 2022.
- A 5-year average of $34.6 million and a median of -$25.0 million in 2023 frame the typical range for Operating Expenses.
- The largest YoY upside for Operating Expenses was 21503.18% in 2022 against a maximum downside of 2893.33% in 2022.
- Year by year, Operating Expenses stood at -$11.8 billion in 2022, then surged by 101.82% to $214.4 million in 2023, then gained by 7.24% to $229.9 million in 2024, then rose by 7.01% to $246.0 million in 2025, then sank by 108.87% to -$21.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$21.8 million, $246.0 million, and -$38.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.10 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.78 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 2.89 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 445.22 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -21.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.83 Mn |
| Dec 31, 2025 | 246.00 Mn |
| Sep 30, 2025 | -38.21 Mn |
| Jun 30, 2025 | -26.58 Mn |
| Mar 31, 2025 | -22.44 Mn |
| Dec 31, 2024 | 229.88 Mn |
| Sep 30, 2024 | -28.32 Mn |
| Jun 30, 2024 | -27.57 Mn |
| Mar 31, 2024 | -24.24 Mn |
| Dec 31, 2023 | 214.37 Mn |
| Sep 30, 2023 | -28.91 Mn |
| Jun 30, 2023 | -25.01 Mn |
| Mar 31, 2023 | -24.47 Mn |
| Dec 31, 2022 | -11.75 Bn |
| Sep 30, 2022 | 12.00 Bn |
| Jun 30, 2022 | -47.17 Mn |
| Mar 31, 2022 | -30.11 Mn |
| Dec 31, 2021 | 420.80 Mn |
| Sep 30, 2021 | -56.05 Mn |
| Jun 30, 2021 | -70.44 Mn |